University at Buffalo - The State University of New York
Skip to Content
UBMD Physicians' Group

Clinical Trials

Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging Study of Piromelatine in Patients with Mild Dementia Due to Alzheimer’s Disease (NEUP11-AD2)

The purpose of this research study is to determine an effective dose of the study drug based on results of safety and efficacy on patients with mild dementia due to Alzheimer's disease as compared to placebo

Eligibility

To pre-qualify for this study, a patient must:
• Be 60 to 85 years of age
• Be diagnosed with mild dementia due to Alzheimer’s disease and experienced a cognitive decline over at least 6 months
• Not have an alternative cause for dementia other than Alzheimer’s disease
• Have a permanent caregiver, who stays under the same roof at least 3 nights a week

Reimbursement

Yes

Investigator

PI: Steven Dubovsky, MD

Contact Information

Name: Sevie Kandefer
Phone: 716-898-4038
Email: sk293@buffalo.edu